Fulltext

Net survival of perinatally and postnatally HIV-infected children: a pooled analysis of individual data from sub-Saharan Africa

Marston, Milly ; Becquet, Renaud ; Zaba, Basia ; Moulton, Lawrence H. ; Gray, Glenda ; Coovadia, Hoosen ; Essex, Max ; Ekouevi, Didier K. ; Jackson, Debra ; Coutsoudis, Anna ; Kilewo, Charles ; Leroy, Valériane ; Wiktor, Stefan ; Nduati, Ruth ; Msellati, Philippe ; Dabis, François ; Newell, Marie-Louise ; Ghys, Peter D.

In: International Journal of Epidemiology, 2011, vol. 40, no. 2, p. 385-396

Aggiungi alla tua lista
    Titre
    • Net survival of perinatally and postnatally HIV-infected children: a pooled analysis of individual data from sub-Saharan Africa
    Auteur
    • Marston, Milly. London School of Hygiene and Tropical Medicine, London, UK, INSERM, unité 897, Centre de recherche "Epidémiologie et Biostatistique", Bordeaux, France, Institut de Santé Publique Epidémiologie Développement (ISPED), Université Victor Segalen Bordeaux 2, Bordeaux, France, ZVITAMBO trial, Zimbabwe; Johns Hopkins Bloomberg School of Public Health, Petra trial, Tanzania, South Africa and Uganda; Perinatal HIV Research Unit, University of Witwatersrand, VTS cohort, South Africa, University of KwaZulu-Natal, University of Witwatersrand, South Africa, Mashi trial, Botswana; Botswana-Harvard AIDS Institute and Harvard School of Health AIDS Initiative, Ditrame Plus cohort, Côte d'Ivoire, Good Start cohort, South Africa; University of the Western Cape, South Africa, Vitamin A trial, South Africa, Mitra Plus cohort, Tanzania, ANRSa trial, Côte d'Ivoire & Burkina Faso, Retro-Ci trial, Côte d'Ivoire; Global AIDS Program, Centers for Disease Control and Prevention, Atlanta, USA, Nairobi trial, Kenya, ANRSb trial, Côte d'Ivoire & Burkina Faso, UMR 145 IRD/Universite de Montpellier 1, montpeillier, France, Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa, Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, London, UK, and UNAIDS, Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland
    • Becquet, Renaud. London School of Hygiene and Tropical Medicine, London, UK, INSERM, unité 897, Centre de recherche "Epidémiologie et Biostatistique", Bordeaux, France, Institut de Santé Publique Epidémiologie Développement (ISPED), Université Victor Segalen Bordeaux 2, Bordeaux, France, ZVITAMBO trial, Zimbabwe; Johns Hopkins Bloomberg School of Public Health, Petra trial, Tanzania, South Africa and Uganda; Perinatal HIV Research Unit, University of Witwatersrand, VTS cohort, South Africa, University of KwaZulu-Natal, University of Witwatersrand, South Africa, Mashi trial, Botswana; Botswana-Harvard AIDS Institute and Harvard School of Health AIDS Initiative, Ditrame Plus cohort, Côte d'Ivoire, Good Start cohort, South Africa; University of the Western Cape, South Africa, Vitamin A trial, South Africa, Mitra Plus cohort, Tanzania, ANRSa trial, Côte d'Ivoire & Burkina Faso, Retro-Ci trial, Côte d'Ivoire; Global AIDS Program, Centers for Disease Control and Prevention, Atlanta, USA, Nairobi trial, Kenya, ANRSb trial, Côte d'Ivoire & Burkina Faso, UMR 145 IRD/Universite de Montpellier 1, montpeillier, France, Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa, Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, London, UK, and UNAIDS, Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland
    • Zaba, Basia. London School of Hygiene and Tropical Medicine, London, UK, INSERM, unité 897, Centre de recherche "Epidémiologie et Biostatistique", Bordeaux, France, Institut de Santé Publique Epidémiologie Développement (ISPED), Université Victor Segalen Bordeaux 2, Bordeaux, France, ZVITAMBO trial, Zimbabwe; Johns Hopkins Bloomberg School of Public Health, Petra trial, Tanzania, South Africa and Uganda; Perinatal HIV Research Unit, University of Witwatersrand, VTS cohort, South Africa, University of KwaZulu-Natal, University of Witwatersrand, South Africa, Mashi trial, Botswana; Botswana-Harvard AIDS Institute and Harvard School of Health AIDS Initiative, Ditrame Plus cohort, Côte d'Ivoire, Good Start cohort, South Africa; University of the Western Cape, South Africa, Vitamin A trial, South Africa, Mitra Plus cohort, Tanzania, ANRSa trial, Côte d'Ivoire & Burkina Faso, Retro-Ci trial, Côte d'Ivoire; Global AIDS Program, Centers for Disease Control and Prevention, Atlanta, USA, Nairobi trial, Kenya, ANRSb trial, Côte d'Ivoire & Burkina Faso, UMR 145 IRD/Universite de Montpellier 1, montpeillier, France, Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa, Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, London, UK, and UNAIDS, Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland
    • Moulton, Lawrence H.. London School of Hygiene and Tropical Medicine, London, UK, INSERM, unité 897, Centre de recherche "Epidémiologie et Biostatistique", Bordeaux, France, Institut de Santé Publique Epidémiologie Développement (ISPED), Université Victor Segalen Bordeaux 2, Bordeaux, France, ZVITAMBO trial, Zimbabwe; Johns Hopkins Bloomberg School of Public Health, Petra trial, Tanzania, South Africa and Uganda; Perinatal HIV Research Unit, University of Witwatersrand, VTS cohort, South Africa, University of KwaZulu-Natal, University of Witwatersrand, South Africa, Mashi trial, Botswana; Botswana-Harvard AIDS Institute and Harvard School of Health AIDS Initiative, Ditrame Plus cohort, Côte d'Ivoire, Good Start cohort, South Africa; University of the Western Cape, South Africa, Vitamin A trial, South Africa, Mitra Plus cohort, Tanzania, ANRSa trial, Côte d'Ivoire & Burkina Faso, Retro-Ci trial, Côte d'Ivoire; Global AIDS Program, Centers for Disease Control and Prevention, Atlanta, USA, Nairobi trial, Kenya, ANRSb trial, Côte d'Ivoire & Burkina Faso, UMR 145 IRD/Universite de Montpellier 1, montpeillier, France, Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa, Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, London, UK, and UNAIDS, Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland
    • Gray, Glenda. London School of Hygiene and Tropical Medicine, London, UK, INSERM, unité 897, Centre de recherche "Epidémiologie et Biostatistique", Bordeaux, France, Institut de Santé Publique Epidémiologie Développement (ISPED), Université Victor Segalen Bordeaux 2, Bordeaux, France, ZVITAMBO trial, Zimbabwe; Johns Hopkins Bloomberg School of Public Health, Petra trial, Tanzania, South Africa and Uganda; Perinatal HIV Research Unit, University of Witwatersrand, VTS cohort, South Africa, University of KwaZulu-Natal, University of Witwatersrand, South Africa, Mashi trial, Botswana; Botswana-Harvard AIDS Institute and Harvard School of Health AIDS Initiative, Ditrame Plus cohort, Côte d'Ivoire, Good Start cohort, South Africa; University of the Western Cape, South Africa, Vitamin A trial, South Africa, Mitra Plus cohort, Tanzania, ANRSa trial, Côte d'Ivoire & Burkina Faso, Retro-Ci trial, Côte d'Ivoire; Global AIDS Program, Centers for Disease Control and Prevention, Atlanta, USA, Nairobi trial, Kenya, ANRSb trial, Côte d'Ivoire & Burkina Faso, UMR 145 IRD/Universite de Montpellier 1, montpeillier, France, Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa, Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, London, UK, and UNAIDS, Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland
    • Coovadia, Hoosen. London School of Hygiene and Tropical Medicine, London, UK, INSERM, unité 897, Centre de recherche "Epidémiologie et Biostatistique", Bordeaux, France, Institut de Santé Publique Epidémiologie Développement (ISPED), Université Victor Segalen Bordeaux 2, Bordeaux, France, ZVITAMBO trial, Zimbabwe; Johns Hopkins Bloomberg School of Public Health, Petra trial, Tanzania, South Africa and Uganda; Perinatal HIV Research Unit, University of Witwatersrand, VTS cohort, South Africa, University of KwaZulu-Natal, University of Witwatersrand, South Africa, Mashi trial, Botswana; Botswana-Harvard AIDS Institute and Harvard School of Health AIDS Initiative, Ditrame Plus cohort, Côte d'Ivoire, Good Start cohort, South Africa; University of the Western Cape, South Africa, Vitamin A trial, South Africa, Mitra Plus cohort, Tanzania, ANRSa trial, Côte d'Ivoire & Burkina Faso, Retro-Ci trial, Côte d'Ivoire; Global AIDS Program, Centers for Disease Control and Prevention, Atlanta, USA, Nairobi trial, Kenya, ANRSb trial, Côte d'Ivoire & Burkina Faso, UMR 145 IRD/Universite de Montpellier 1, montpeillier, France, Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa, Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, London, UK, and UNAIDS, Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland
    • Essex, Max. London School of Hygiene and Tropical Medicine, London, UK, INSERM, unité 897, Centre de recherche "Epidémiologie et Biostatistique", Bordeaux, France, Institut de Santé Publique Epidémiologie Développement (ISPED), Université Victor Segalen Bordeaux 2, Bordeaux, France, ZVITAMBO trial, Zimbabwe; Johns Hopkins Bloomberg School of Public Health, Petra trial, Tanzania, South Africa and Uganda; Perinatal HIV Research Unit, University of Witwatersrand, VTS cohort, South Africa, University of KwaZulu-Natal, University of Witwatersrand, South Africa, Mashi trial, Botswana; Botswana-Harvard AIDS Institute and Harvard School of Health AIDS Initiative, Ditrame Plus cohort, Côte d'Ivoire, Good Start cohort, South Africa; University of the Western Cape, South Africa, Vitamin A trial, South Africa, Mitra Plus cohort, Tanzania, ANRSa trial, Côte d'Ivoire & Burkina Faso, Retro-Ci trial, Côte d'Ivoire; Global AIDS Program, Centers for Disease Control and Prevention, Atlanta, USA, Nairobi trial, Kenya, ANRSb trial, Côte d'Ivoire & Burkina Faso, UMR 145 IRD/Universite de Montpellier 1, montpeillier, France, Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa, Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, London, UK, and UNAIDS, Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland
    • Ekouevi, Didier K.. London School of Hygiene and Tropical Medicine, London, UK, INSERM, unité 897, Centre de recherche "Epidémiologie et Biostatistique", Bordeaux, France, Institut de Santé Publique Epidémiologie Développement (ISPED), Université Victor Segalen Bordeaux 2, Bordeaux, France, ZVITAMBO trial, Zimbabwe; Johns Hopkins Bloomberg School of Public Health, Petra trial, Tanzania, South Africa and Uganda; Perinatal HIV Research Unit, University of Witwatersrand, VTS cohort, South Africa, University of KwaZulu-Natal, University of Witwatersrand, South Africa, Mashi trial, Botswana; Botswana-Harvard AIDS Institute and Harvard School of Health AIDS Initiative, Ditrame Plus cohort, Côte d'Ivoire, Good Start cohort, South Africa; University of the Western Cape, South Africa, Vitamin A trial, South Africa, Mitra Plus cohort, Tanzania, ANRSa trial, Côte d'Ivoire & Burkina Faso, Retro-Ci trial, Côte d'Ivoire; Global AIDS Program, Centers for Disease Control and Prevention, Atlanta, USA, Nairobi trial, Kenya, ANRSb trial, Côte d'Ivoire & Burkina Faso, UMR 145 IRD/Universite de Montpellier 1, montpeillier, France, Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa, Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, London, UK, and UNAIDS, Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland
    • Jackson, Debra. London School of Hygiene and Tropical Medicine, London, UK, INSERM, unité 897, Centre de recherche "Epidémiologie et Biostatistique", Bordeaux, France, Institut de Santé Publique Epidémiologie Développement (ISPED), Université Victor Segalen Bordeaux 2, Bordeaux, France, ZVITAMBO trial, Zimbabwe; Johns Hopkins Bloomberg School of Public Health, Petra trial, Tanzania, South Africa and Uganda; Perinatal HIV Research Unit, University of Witwatersrand, VTS cohort, South Africa, University of KwaZulu-Natal, University of Witwatersrand, South Africa, Mashi trial, Botswana; Botswana-Harvard AIDS Institute and Harvard School of Health AIDS Initiative, Ditrame Plus cohort, Côte d'Ivoire, Good Start cohort, South Africa; University of the Western Cape, South Africa, Vitamin A trial, South Africa, Mitra Plus cohort, Tanzania, ANRSa trial, Côte d'Ivoire & Burkina Faso, Retro-Ci trial, Côte d'Ivoire; Global AIDS Program, Centers for Disease Control and Prevention, Atlanta, USA, Nairobi trial, Kenya, ANRSb trial, Côte d'Ivoire & Burkina Faso, UMR 145 IRD/Universite de Montpellier 1, montpeillier, France, Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa, Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, London, UK, and UNAIDS, Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland
    • Coutsoudis, Anna. London School of Hygiene and Tropical Medicine, London, UK, INSERM, unité 897, Centre de recherche "Epidémiologie et Biostatistique", Bordeaux, France, Institut de Santé Publique Epidémiologie Développement (ISPED), Université Victor Segalen Bordeaux 2, Bordeaux, France, ZVITAMBO trial, Zimbabwe; Johns Hopkins Bloomberg School of Public Health, Petra trial, Tanzania, South Africa and Uganda; Perinatal HIV Research Unit, University of Witwatersrand, VTS cohort, South Africa, University of KwaZulu-Natal, University of Witwatersrand, South Africa, Mashi trial, Botswana; Botswana-Harvard AIDS Institute and Harvard School of Health AIDS Initiative, Ditrame Plus cohort, Côte d'Ivoire, Good Start cohort, South Africa; University of the Western Cape, South Africa, Vitamin A trial, South Africa, Mitra Plus cohort, Tanzania, ANRSa trial, Côte d'Ivoire & Burkina Faso, Retro-Ci trial, Côte d'Ivoire; Global AIDS Program, Centers for Disease Control and Prevention, Atlanta, USA, Nairobi trial, Kenya, ANRSb trial, Côte d'Ivoire & Burkina Faso, UMR 145 IRD/Universite de Montpellier 1, montpeillier, France, Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa, Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, London, UK, and UNAIDS, Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland
    • Kilewo, Charles. London School of Hygiene and Tropical Medicine, London, UK, INSERM, unité 897, Centre de recherche "Epidémiologie et Biostatistique", Bordeaux, France, Institut de Santé Publique Epidémiologie Développement (ISPED), Université Victor Segalen Bordeaux 2, Bordeaux, France, ZVITAMBO trial, Zimbabwe; Johns Hopkins Bloomberg School of Public Health, Petra trial, Tanzania, South Africa and Uganda; Perinatal HIV Research Unit, University of Witwatersrand, VTS cohort, South Africa, University of KwaZulu-Natal, University of Witwatersrand, South Africa, Mashi trial, Botswana; Botswana-Harvard AIDS Institute and Harvard School of Health AIDS Initiative, Ditrame Plus cohort, Côte d'Ivoire, Good Start cohort, South Africa; University of the Western Cape, South Africa, Vitamin A trial, South Africa, Mitra Plus cohort, Tanzania, ANRSa trial, Côte d'Ivoire & Burkina Faso, Retro-Ci trial, Côte d'Ivoire; Global AIDS Program, Centers for Disease Control and Prevention, Atlanta, USA, Nairobi trial, Kenya, ANRSb trial, Côte d'Ivoire & Burkina Faso, UMR 145 IRD/Universite de Montpellier 1, montpeillier, France, Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa, Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, London, UK, and UNAIDS, Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland
    • Leroy, Valériane. London School of Hygiene and Tropical Medicine, London, UK, INSERM, unité 897, Centre de recherche "Epidémiologie et Biostatistique", Bordeaux, France, Institut de Santé Publique Epidémiologie Développement (ISPED), Université Victor Segalen Bordeaux 2, Bordeaux, France, ZVITAMBO trial, Zimbabwe; Johns Hopkins Bloomberg School of Public Health, Petra trial, Tanzania, South Africa and Uganda; Perinatal HIV Research Unit, University of Witwatersrand, VTS cohort, South Africa, University of KwaZulu-Natal, University of Witwatersrand, South Africa, Mashi trial, Botswana; Botswana-Harvard AIDS Institute and Harvard School of Health AIDS Initiative, Ditrame Plus cohort, Côte d'Ivoire, Good Start cohort, South Africa; University of the Western Cape, South Africa, Vitamin A trial, South Africa, Mitra Plus cohort, Tanzania, ANRSa trial, Côte d'Ivoire & Burkina Faso, Retro-Ci trial, Côte d'Ivoire; Global AIDS Program, Centers for Disease Control and Prevention, Atlanta, USA, Nairobi trial, Kenya, ANRSb trial, Côte d'Ivoire & Burkina Faso, UMR 145 IRD/Universite de Montpellier 1, montpeillier, France, Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa, Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, London, UK, and UNAIDS, Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland
    • Wiktor, Stefan. London School of Hygiene and Tropical Medicine, London, UK, INSERM, unité 897, Centre de recherche "Epidémiologie et Biostatistique", Bordeaux, France, Institut de Santé Publique Epidémiologie Développement (ISPED), Université Victor Segalen Bordeaux 2, Bordeaux, France, ZVITAMBO trial, Zimbabwe; Johns Hopkins Bloomberg School of Public Health, Petra trial, Tanzania, South Africa and Uganda; Perinatal HIV Research Unit, University of Witwatersrand, VTS cohort, South Africa, University of KwaZulu-Natal, University of Witwatersrand, South Africa, Mashi trial, Botswana; Botswana-Harvard AIDS Institute and Harvard School of Health AIDS Initiative, Ditrame Plus cohort, Côte d'Ivoire, Good Start cohort, South Africa; University of the Western Cape, South Africa, Vitamin A trial, South Africa, Mitra Plus cohort, Tanzania, ANRSa trial, Côte d'Ivoire & Burkina Faso, Retro-Ci trial, Côte d'Ivoire; Global AIDS Program, Centers for Disease Control and Prevention, Atlanta, USA, Nairobi trial, Kenya, ANRSb trial, Côte d'Ivoire & Burkina Faso, UMR 145 IRD/Universite de Montpellier 1, montpeillier, France, Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa, Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, London, UK, and UNAIDS, Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland
    • Nduati, Ruth. London School of Hygiene and Tropical Medicine, London, UK, INSERM, unité 897, Centre de recherche "Epidémiologie et Biostatistique", Bordeaux, France, Institut de Santé Publique Epidémiologie Développement (ISPED), Université Victor Segalen Bordeaux 2, Bordeaux, France, ZVITAMBO trial, Zimbabwe; Johns Hopkins Bloomberg School of Public Health, Petra trial, Tanzania, South Africa and Uganda; Perinatal HIV Research Unit, University of Witwatersrand, VTS cohort, South Africa, University of KwaZulu-Natal, University of Witwatersrand, South Africa, Mashi trial, Botswana; Botswana-Harvard AIDS Institute and Harvard School of Health AIDS Initiative, Ditrame Plus cohort, Côte d'Ivoire, Good Start cohort, South Africa; University of the Western Cape, South Africa, Vitamin A trial, South Africa, Mitra Plus cohort, Tanzania, ANRSa trial, Côte d'Ivoire & Burkina Faso, Retro-Ci trial, Côte d'Ivoire; Global AIDS Program, Centers for Disease Control and Prevention, Atlanta, USA, Nairobi trial, Kenya, ANRSb trial, Côte d'Ivoire & Burkina Faso, UMR 145 IRD/Universite de Montpellier 1, montpeillier, France, Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa, Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, London, UK, and UNAIDS, Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland
    • Msellati, Philippe. London School of Hygiene and Tropical Medicine, London, UK, INSERM, unité 897, Centre de recherche "Epidémiologie et Biostatistique", Bordeaux, France, Institut de Santé Publique Epidémiologie Développement (ISPED), Université Victor Segalen Bordeaux 2, Bordeaux, France, ZVITAMBO trial, Zimbabwe; Johns Hopkins Bloomberg School of Public Health, Petra trial, Tanzania, South Africa and Uganda; Perinatal HIV Research Unit, University of Witwatersrand, VTS cohort, South Africa, University of KwaZulu-Natal, University of Witwatersrand, South Africa, Mashi trial, Botswana; Botswana-Harvard AIDS Institute and Harvard School of Health AIDS Initiative, Ditrame Plus cohort, Côte d'Ivoire, Good Start cohort, South Africa; University of the Western Cape, South Africa, Vitamin A trial, South Africa, Mitra Plus cohort, Tanzania, ANRSa trial, Côte d'Ivoire & Burkina Faso, Retro-Ci trial, Côte d'Ivoire; Global AIDS Program, Centers for Disease Control and Prevention, Atlanta, USA, Nairobi trial, Kenya, ANRSb trial, Côte d'Ivoire & Burkina Faso, UMR 145 IRD/Universite de Montpellier 1, montpeillier, France, Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa, Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, London, UK, and UNAIDS, Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland
    • Dabis, François. London School of Hygiene and Tropical Medicine, London, UK, INSERM, unité 897, Centre de recherche "Epidémiologie et Biostatistique", Bordeaux, France, Institut de Santé Publique Epidémiologie Développement (ISPED), Université Victor Segalen Bordeaux 2, Bordeaux, France, ZVITAMBO trial, Zimbabwe; Johns Hopkins Bloomberg School of Public Health, Petra trial, Tanzania, South Africa and Uganda; Perinatal HIV Research Unit, University of Witwatersrand, VTS cohort, South Africa, University of KwaZulu-Natal, University of Witwatersrand, South Africa, Mashi trial, Botswana; Botswana-Harvard AIDS Institute and Harvard School of Health AIDS Initiative, Ditrame Plus cohort, Côte d'Ivoire, Good Start cohort, South Africa; University of the Western Cape, South Africa, Vitamin A trial, South Africa, Mitra Plus cohort, Tanzania, ANRSa trial, Côte d'Ivoire & Burkina Faso, Retro-Ci trial, Côte d'Ivoire; Global AIDS Program, Centers for Disease Control and Prevention, Atlanta, USA, Nairobi trial, Kenya, ANRSb trial, Côte d'Ivoire & Burkina Faso, UMR 145 IRD/Universite de Montpellier 1, montpeillier, France, Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa, Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, London, UK, and UNAIDS, Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland
    • Newell, Marie-Louise. London School of Hygiene and Tropical Medicine, London, UK, INSERM, unité 897, Centre de recherche "Epidémiologie et Biostatistique", Bordeaux, France, Institut de Santé Publique Epidémiologie Développement (ISPED), Université Victor Segalen Bordeaux 2, Bordeaux, France, ZVITAMBO trial, Zimbabwe; Johns Hopkins Bloomberg School of Public Health, Petra trial, Tanzania, South Africa and Uganda; Perinatal HIV Research Unit, University of Witwatersrand, VTS cohort, South Africa, University of KwaZulu-Natal, University of Witwatersrand, South Africa, Mashi trial, Botswana; Botswana-Harvard AIDS Institute and Harvard School of Health AIDS Initiative, Ditrame Plus cohort, Côte d'Ivoire, Good Start cohort, South Africa; University of the Western Cape, South Africa, Vitamin A trial, South Africa, Mitra Plus cohort, Tanzania, ANRSa trial, Côte d'Ivoire & Burkina Faso, Retro-Ci trial, Côte d'Ivoire; Global AIDS Program, Centers for Disease Control and Prevention, Atlanta, USA, Nairobi trial, Kenya, ANRSb trial, Côte d'Ivoire & Burkina Faso, UMR 145 IRD/Universite de Montpellier 1, montpeillier, France, Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa, Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, London, UK, and UNAIDS, Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland
    • Ghys, Peter D.. London School of Hygiene and Tropical Medicine, London, UK, INSERM, unité 897, Centre de recherche "Epidémiologie et Biostatistique", Bordeaux, France, Institut de Santé Publique Epidémiologie Développement (ISPED), Université Victor Segalen Bordeaux 2, Bordeaux, France, ZVITAMBO trial, Zimbabwe; Johns Hopkins Bloomberg School of Public Health, Petra trial, Tanzania, South Africa and Uganda; Perinatal HIV Research Unit, University of Witwatersrand, VTS cohort, South Africa, University of KwaZulu-Natal, University of Witwatersrand, South Africa, Mashi trial, Botswana; Botswana-Harvard AIDS Institute and Harvard School of Health AIDS Initiative, Ditrame Plus cohort, Côte d'Ivoire, Good Start cohort, South Africa; University of the Western Cape, South Africa, Vitamin A trial, South Africa, Mitra Plus cohort, Tanzania, ANRSa trial, Côte d'Ivoire & Burkina Faso, Retro-Ci trial, Côte d'Ivoire; Global AIDS Program, Centers for Disease Control and Prevention, Atlanta, USA, Nairobi trial, Kenya, ANRSb trial, Côte d'Ivoire & Burkina Faso, UMR 145 IRD/Universite de Montpellier 1, montpeillier, France, Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa, Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, London, UK, and UNAIDS, Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland
    Type de document
    • Postprint
    Langue
    • Inglese
    Publié dans
    • International Journal of Epidemiology, 2011, vol. 40, no. 2, p. 385-396. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:290445
    Summary
    Background Previously, HIV epidemic models have used a double Weibull curve to represent high initial and late mortality of HIV-infected children, without distinguishing timing of infection (peri- or post-natally). With more data on timing of infection, which may be associated with disease progression, a separate representation of children infected early and late was proposed. Methods Paediatric survival post-HIV infection without anti-retroviral treatment was calculated using pooled data from 12 studies with known timing of HIV infection. Children were grouped into perinatally or post-natally infected. Net mortality was calculated using cause-deleted life tables to give survival as if HIV was the only competing cause of death. To extend the curve beyond the available data, children surviving beyond 2.5 years post infection were assumed to have the same survival as young adults. Double Weibull curves were fitted to both extended survival curves to represent survival of children infected perinatally or through breastfeeding. Results Those children infected perinatally had a much higher risk of dying than those infected through breastfeeding, even allowing for background mortality. The final-fitted double Weibull curves gave 75% survival at 5 months after infection for perinatally infected, and 1.1 years for post-natally infected children. An estimated 25% of the early infected children would still be alive at 10.6 years compared with 16.9 years for those infected through breastfeeding. Conclusions The increase in available data has enabled separation of child mortality patterns by timing of infection allowing improvement and more flexibility in modelling of paediatric HIV infection and survival